Witty and Dekkers bemoan austerity measures, but remain tight lipped on way forward
This article was originally published in Scrip
Executive Summary
GSK CEO, Andrew Witty, this week complained that European governments treated the purchase of life saving drugs like any other procurement exercise, while Dr Marjin Dekkers, chairman of Bayer’s management board, pointed to their failure to value innovation. However, neither company would comment on potential alternatives or action plans for cash strapped policy makers.